

Anti-TNFRSF9/4-1BB/CD137 Antibody (Utomilumab)

Introduction

Utomilumab (PF 05082566) is a humanized IgG2 mAb agonist targeting the T cell co-stimulatory receptor 4-1BB/CD137. Utomilumab is being investigated in patients with relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL).

Product parameters

Alternative Names	PF-5082566, F-2566
Target Accession	Q07011
Target	TNFRSF9 / 4-1BB / CD137
CAS number	1417318-27-4
Molecular Weight	142.78 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TNFRSF9 / 4-1BB / CD137, His Tag at 2 ug/mL can bind utomilumab, EC50=0.006915 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

